Baird Downgrades Quest Diagnostics (DGX) to Neutral

Baird analyst Eric Coldwell downgraded Quest Diagnostics (NYSE: DGX) from Outperform to Neutral with a price target of $194.00.

The analyst comments: "We are downgrading DGX to Neutral and maintaining our Outperform rating on LH.
Arguably, this is a 50/50 call, and we could lean either way on each. Objective math says risk/reward is too balanced to stay positive; instinct says there’s a lot going right in the space and the tape tells us the Street is onboard despite PAMA risks. We’re giving LH some leash for a host of reasons, though tactically we’d be better buyers lower."

For an analyst ratings summary and ratings history on Quest Diagnostics click here. For more ratings news on Quest Diagnostics click here.

Shares of Quest Diagnostics closed at $180.23 yesterday.

You May Also Be Interested In

• 22nd Century Group files prospectus for warrant share resale
• Liberty All-Star Equity Fund appoints Loomis Sayles as new manager
• Lockheed Martin wins $2.8B in Defense contracts for F-35, helicopters